September 29, 2025

Tourmaline Attracted Bidding War Before $1.4B Acquisition by Novartis

2 weeks ago talkbio0Tagged Acquisition, Antibodies, ASCVD, Bio, Cardiovascular Agents, interleukin-6, Novartis, pacibekitug, tourmaline

Tourmaline Bio; Novartis; acquisition; bidding war; $1.4 billion; pacibekitug; cardiovascular drug; IL-6 antibody; ASCVD; biotech

MoonLake shares crash after mixed results in pivotal hidradenitis suppurativa studies

2 weeks ago talkbio0Tagged Bimzelx, Clinical Trials, Cosentyx, drug approval outlook, drug market, Hidradenitis Suppurativa, inhibitors, Interleukin-17, MoonLake Immunotherapeutics, Placebos, Response process, sonelokimab

MoonLake Immunotherapeutics; Sonelokimab; hidradenitis suppurativa; Phase 3 trial; clinical trial results; biotech shares; placebo response; drug approval outlook; IL-17 inhibitors; Bimzelx; Cosentyx; drug market potential

GSK Appoints Luke Miels as New CEO, Succeeding Emma Walmsley on Jan. 1, 2026

2 weeks ago talkbio0Tagged Appointments, CEO, Emma Walmsley, Leadership Transition, Luke Miels, R&D pipeline, SmithKline Beecham, specialty medicines, Vaccines

GSK; Luke Miels; Emma Walmsley; CEO appointment; pharmaceuticals; leadership transition; specialty medicines; vaccines; R&D pipeline

Genmab CEO on the $8B Acquisition of Merus: Strategy Behind the ‘Very Fair’ Deal and Plans to Polish a Rough Diamond

2 weeks ago talkbio0Tagged Acquisition, Antibodies, Bispecific, Breakthrough Therapy, Cancer of Neck, CEO, expansion, Genmab, Head, Merus, Neoplasms, Perspective, Petosemtamab, pipeline, United States Food and Drug Administration

Genmab; Merus; petosemtamab; acquisition; oncology; head and neck cancer; bispecific antibody; FDA Breakthrough Therapy; pipeline expansion; biotech; $8B deal; CEO perspective

White House ‘Most Favored Nation’ Deadline Drives Pharma Concessions Amid Threats of Enforcement

2 weeks ago talkbio0Tagged deadline, drug manufacturers, drug price, Medicaid, Medicare, Nation, Pharma Concessions, pharmaceutical companies, prescription drug costs, Trump administration, White House

most favored nation; drug pricing; White House; executive order; pharmaceutical companies; Medicaid; Medicare; drug manufacturers; Trump administration; prescription drug costs; deadline; pharma concessions

Rezon Bio Launches Two State-of-the-Art CDMO Facilities for Biologics in Europe

2 weeks ago talkbio0Tagged Biological Factors, Biosimilars, CDMO, Contract agreement, Digital innovation, Europe, Gdańsk, Guanosine Monophosphate, Manufacturing, Multiple Acyl Coenzyme A Dehydrogenase Deficiency, Rezon Bio, United States Food and Drug Administration, Warsaw-Duchnice

Rezon Bio; biologics; CDMO; contract manufacturing; Gdańsk; Warsaw-Duchnice; Europe; digital innovation; GMP manufacturing; biosimilars; EMA; FDA

Continuous Bioprocessing for Bispecific Antibodies: Innovations Accelerating Therapeutic Antibody Production (2024–2025)

2 weeks ago talkbio0Tagged Antibodies, Bispecific, antibody engineering, Automation, bioprocess, bioprocessing, Continuous, high-throughput, innovation, oncology therapeutics, production, Protein Purification, scale-up, Therapeutic Antibody

continuous bioprocessing; bispecific antibodies; therapeutic antibody production; bioprocess innovation; high-throughput production; antibody engineering; scale-up; oncology therapeutics; protein purification; automation

Biogen Shuffles Staff and Exits AAV Gene Therapy Programs After Strategic Shift

2 weeks ago talkbio0Tagged AAVS1 gene, Biogen, Biotech Layoffs, Discontinuation (procedure), gene therapy, layoffs, Pharma, staff reorganization

Biogen; AAV gene therapy; layoffs; staff reorganization; biotech layoffs; pharma restructuring; gene therapy discontinuation

GSK CEO Emma Walmsley Steps Down After 9 Years; Luke Miels to Succeed

2 weeks ago talkbio0Tagged CEO, Drug Industry, Emma Walmsley, Haleon demerger, Leadership Change, Luke Miels, SmithKline Beecham, specialty medicines, Succession planning, Transition Mutation, Vaccines

Emma Walmsley; GSK; CEO transition; Luke Miels; leadership change; pharmaceutical industry; Haleon demerger; specialty medicines; vaccines; succession planning

New Confirmatory Study Suggests Progress in Applied Therapeutics–FDA Alignment for Rare Disease Drug

2 weeks ago talkbio0Tagged Apply, Clinical Trials, CMT-SORD, confirmatory study, Govorestat, Infrequent, regulatory alignment, United States Food and Drug Administration

Applied Therapeutics; govorestat; CMT-SORD; rare disease; FDA; confirmatory study; clinical trial; regulatory alignment